PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer
Meng, X.; Hu, X.; Zhang, S.; Zhang, S.; Wang, X.; Ma, S.; Qin, C.
Show abstract
PROTACs, degrading target protein to treat diseases, represent a highly promising drug design strategy. However, the degradation of target proteins by PROTACs in non-disease tissues may lead to systemic toxicity. Herein, capitalizing on the characteristic overexpression of PSMA in prostate cancer tumor tissues, we devised a PSMA-guided PROTACs specific targeting to prostate cancer. By conjugating AR degraders and BET degraders separately with PSMA ligands via cleavable linkers, two classes of PSMA-guided PROTACs were obtained. In vitro experiments demonstrated that PSMA-guided PROTAC molecules selectively degraded target proteins in PSMA-overexpressing prostate cancer cells, without affecting target proteins in non-PSMA-overexpressing cells. In vivo studies revealed that compared to conventional PROTACs, PSMA-guided PROTACs enhanced drug exposure in prostate cancer tumor tissues, prolonged half-life, and consequently achieved stronger and more sustained therapeutic effects. The PSMA-guided PROTAC strategy provides a novel avenue for disease tissue-specific PROTAC research, holding significant implications for targeted therapy in prostate cancer.
Matching journals
The top 17 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry 95%
- Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance 94%
- Pancreatic Tumor Eradication via Selective PIN1 Inhibition in Cancer Associated Fibroblasts and T Lymphocytes Engagement 94%
Similar papers in this journal
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells 92%
- Selective targeting of an oncogenic KRAS mutant allele by CRISPR/Cas9 induces efficient tumor regression 91%
- GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy 91%
Similar papers in this journal
Similar papers in this journal
- Development of potent and selective CK1α Molecular Glue Degraders 95%
- Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease 94%
- Discovery of CD28-Targeted Small Molecule Inhibitors of T Cell Co-stimulation Using Affinity Selection-Mass Spectrometry (AS-MS) and Ex Vivo Validation 93%
Similar papers in this journal
- Discovery of intratumoral oncolytic bacteria toward targeted anticancer theranostics 93%
- Target Identification and Mechanistic Characterization of Indole Terpenoid Mimics: Proper Spindle Microtubule Assembly Is Essential for Cdh1-Mediated Proteolysis of CENP-A 92%
- Novel naphthyridones targeting Pannexin 1 for colitis management 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.